Country: United States
Language: English
Source: NLM (National Library of Medicine)
PENICILLAMINE (UNII: GNN1DV99GX) (PENICILLAMINE - UNII:GNN1DV99GX)
ANI Pharmaceuticals, Inc.
ORAL
PRESCRIPTION DRUG
Penicillamine capsules are indicated in the treatment of Wilson’s disease, cystinuria, and in patients with severe, active rheumatoid arthritis who have failed to respond to an adequate trial of conventional therapy. Available evidence suggests that penicillamine capsules are not of value in ankylosing spondylitis. Wilson’s Disease - Wilson’s disease (hepatolenticular degeneration) occurs in individuals who have inherited an autosomal recessive defect that leads to an accumulation of copper far in excess of metabolic requirements. The excess copper is deposited in several organs and tissues, and eventually produces pathological effects primarily in the liver, where damage progresses to postnecrotic cirrhosis, and in the brain, where degeneration is widespread. Copper is also deposited as characteristic, asymptomatic, golden-brown Kayser-Fleischer rings in the corneas of all patients with cerebral symptomatology and some patients who are either asymptomatic or manifest only hepatic symptomatology. Two types o
Penicillamine capsules, 250 mg, USP, are ivory-colored capsules containing a white to off-white powder, and are imprinted with AMG on the cap and 309 on the body in black ink. They are supplied as follows: NDC 43975-309-10 in bottles of 100. Storage Keep container tightly closed. Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature]. Dispense in a tight, light-resistant container, as defined in the USP. KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN. Rx Only Manufactured For: Amerigen Pharmaceuticals, Inc. Lyndhurst, NJ 07071 USA OS1033/00 Rev. 02/2019
Abbreviated New Drug Application
PENICILLAMINE- PENICILLAMINE CAPSULE ANI PHARMACEUTICALS, INC. ---------- PENICILLAMINE CAPSULES, USP Physicians planning to use penicillamine should thoroughly familiarized themselves with its toxicity, special dosage considerations, and therapeutic benefits. Penicillamine should never be used casually. Each patient should remain constantly under the close supervision of the physician. Patients should be warned to report promptly any symptoms suggesting toxicity. DESCRIPTION Penicillamine is a chelating agent used in the treatment of Wilson's disease. It is also used to reduce cystine excretion in cystinuria and to treat patients with severe, active rheumatoid arthritis unresponsive to conventional therapy (see INDICATIONS). It is 3- mercapto-D-valine. It is a white or practically white, crystalline powder, freely soluble in water, slightly soluble in alcohol, and insoluble in ether, acetone, benzene, and carbon tetrachloride. Although its configuration is D, it is levorotatory as usually measured: [α] 25°= -62.5° ± 2° (c = 1, 1N NaOH), D calculated on a dried basis. The empirical formula is C H NO S, giving it a molecular weight of 149.21. The structural formula is: It reacts readily with formaldehyde or acetone to form a thiazolidine-carboxylic acid. Penicillamine capsules, USP, for oral administration contain 250 mg of penicillamine. Each capsule contains the following inactive ingredients: magnesium stearate and povidone. The capsule shells contain D&C Yellow No. 10, titanium dioxide, gelatin, shellac, propylene glycol, potassium hydroxide and black iron oxide. CLINICAL PHARMACOLOGY Penicillamine is a chelating agent recommended for the removal of excess copper in patients with Wilson’s disease. From _in vitro _studies which indicate that one atom of copper combines with two molecules of penicillamine, it would appear that one gram of penicillamine should be followed by the excretion of about 200 milligrams of copper; 5 11 2 however, the actual amount excreted is about one percent of this. Penicillami Read the complete document